Prioritization of preventive OCV use in hotspots

Elizabeth C. Lee

Johns Hopkins Bloomberg School of Public Health 3 December 2020







Goal: To develop standardized global guidance for the preventive use of oral cholera vaccines (OCV)

Motivation: Cholera-affected countries and GTFCC partners are in need of guiding principles for the allocation of OCV and other support for preventive OCV campaigns



 What epidemiological criteria will be used to determine target populations eligible to receive preventive vaccines?

- How to balance competing priorities:
 - a) Equity of vaccine access across countries
 - b) Maximization of vaccine impact and cost-effectiveness
 - c) Flexibility for countries to adapt OCV plans to the local context
 - d) Support for countries nearing elimination



Updates from the past year

- Discussion of guiding principles at last year's annual meeting (June 2019)
- Members of OCV WG drafted an initial proposal of this guidance (Dec 2019)
- Piloted the preliminary guidance in Ethiopia (Jan 2020)
- Revisions to guidance (ongoing)



Initial proposal from Dec 2019

Countries would submit a phase 1 preventive OCV request for no more than 10% of the country population with proposed campaign targets according to 2 categories:

- 1) Populations with **automatic eligibility**: Must have high mean annual incidence or moderate mean annual incidence and high persistence
- Populations requiring additional justification: Known gaps in surveillance, poor access to WASH, high importation risk despite low incidence



Feedback and revisions

- OCV request guidance needs to be better integrated with hotspot identification guidance
 - Metrics and standards should be aligned across guidance
 - Confusion about why "hotspots" needed to be selected twice
- Strict thresholds for mean annual incidence may not be equitable to all countries



Next steps

- Agree upon the priorities for balancing the four competing priorities (equity, health impact & cost-effectiveness, flexibility, and elimination goals)
- GTFCC will draft a document with the guiding principles and interim guidance on policy for preventive OCV use to circulate to the OCV WG by March 2021
- Hotspot subgroup in the surveillance WG, in conjunction with the OCV WG will work on a more permanent and data-driven guidance document



Open Discussion...

- a) Equity of vaccine access across countries
- b) Maximization of vaccine impact and costeffectiveness
- c) Flexibility for countries to adapt OCV plans to the local context
- d) Support for countries nearing elimination

